OUTSTEP 项目：采用以患者为中心的多维度方法了解患者体验、实际应用情况以及索玛鲁肽在肥胖症管理中的疗效 .pdf

1、Scan QR code or visit the web site below for:Digital posterhttps:/ V et al.Adv Ther 2025;42:53415364.1Department of Medicine,Faculty of Medicine and Dentistry,University of Alberta,Edmonton,AB,Canada;2Center for Clinical Research and Prevention,Copenhagen University Hospital-Bispebjerg and Frederiks

2、berg,Copenhagen,Denmark;3Novo Nordisk Health Care,Zrich,Switzerland;4Novo Nordisk Service Centre India Private Ltd.,Bengaluru,India;5Department of Precision Health,Nutrition and Health Research Group,Luxembourg Institute of Health,Strassen,Luxembourg;6Luxembourgish Association for the Study of Obesi

3、ty.Enscherange,Luxembourg;7Family Medicine,Dalhousie University,Halifax,NS,Canada;8Associao Brasileira para o Estudo da Obesidade e Sndrome Metablica(ABESO),So Paulo,Brazil;9Obesity Center,Hospital 9 de Julho,So Paulo,Brazil.The OUTSTEP programme is funded by Novo Nordisk Health Care AG and is regis

4、tered with ClinicalTrials.gov(NCT07154238)and PROSPERO(CRD420251117231).The authors would like to thank Swagata Dey of Novo Nordisk Service Centre India Private Ltd.,Bangalore,India,for her contributions to the development of this poster.Medical writing support was provided by Roxanna Munir,PhD,of A

5、pollo,of OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(www.ismpp.org/gpp-2022).AMS has received funding as a speaker/consultant from AbbVie,Amgen,AstraZeneca,Bayer,Boehringer-Ingelheim,Caliway Biopharmaceuticals,Currax Pharmaceu

6、ticals,DKSH,Eli Lilly,Eva Pharma,Fortrea,Novo Nordisk,Oviva,Roche,and Vivus.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Background and aim Obesity is a chronic,multifactorial,relapsing disease,and treatments like semaglutide have transformed its management.1